CTLA4 and Miyoshi myopathy: However, later on, anti-PD-1 monoclonal antibodies, pembrolizumab and nivolumab, were approved for the treatment of MM, based on pivotal trials that showed anti-PD-1 monotherapy achieved an objective response rate (ORR) of 35 to 42% and a 7-year OS of 37.8% [6,7], overcoming results from anti-CTLA-4 monotherapy.